StockNews.AI
NAII
StockNews.AI
97 days

Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results

1. NAII reported a net loss of $2.2 million for Q3 2025. 2. Net sales increased by 14% to $28.8 million year-over-year. 3. Private-label manufacturing sales jumped 20%, driven by new customer orders. 4. CarnoSyn® sales dropped 36% in Q3 due to decreased customer orders. 5. Company expects continued losses despite growth in top line revenue.

10m saved
Insight
Article

FAQ

Why Bearish?

Increased sales are overshadowed by rising losses and declining key revenue lines.

How important is it?

The reported losses and cautious future outlook indicate potential weakness affecting investor sentiment.

Why Short Term?

Immediate challenges from operating losses and decreased customer orders will impact short-term performance.

Related Companies

APRDNBRIGNC
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 per diluted share, on net sales of $28.8 million for the third quarter of fiscal year 2025 compared to a net loss of $1.6 million, or $0.27 per diluted share, in the third quarter of the prior fiscal year. Net sales during the three months ended March 31, 2025, increased $3.6 million, or 14%, to $28.8 million as compared to $25.1 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales increased 20% to $27.1 million, primarily due to increased orders from several of our larger customers and shipments to new customers. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 36% to $1.7 million during the third quarter of fiscal year 2025, as compared to $2.7 million for the third quarter of fiscal year 2024, primarily due to a decrease in orders from existing customers. Our net loss for the nine months ended March 31, 2025, was $6.4 million, or $1.07 per diluted share, compared to a net loss of $5.3 million, or $0.91 per diluted share, for the nine months ended March 31, 2024. Net sales during the nine months ended March 31, 2025, increased $11.7 million, or 14%, to $96.0 million as compared to $84.3 million recorded in the comparable prior year period. During the nine months ended March 31, 2025, private-label contract manufacturing sales increased 16% to $90.0 million, as compared to $77.7 million in the comparable prior period. CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 9% to $6.0 million during the first nine months of fiscal 2025, as compared to $6.6 million for the first nine months of fiscal 2024. While we grew our net sales during the three and nine months ended March 31, 2025 as compared to the prior year periods, we continued to experience a loss from operations due primarily to the underutilization of our factory capacities, lower beta-alanine royalty and licensing revenue, and increased operating expenses primarily related to legal costs, selling, general and administrative, salaries and wages. Manufacturing costs were also negatively impacted by increased labor, foreign currency exchange rates, operating supplies, rent, and freight costs. Although our overall sales forecast for the fourth quarter of fiscal 2025 includes an increase in sales as compared to fiscal 2024, we anticipate we will experience an overall net loss for fiscal 2025. As of March 31, 2025, we had cash of $10.6 million and working capital of $35.2 million, compared to $12.0 million and $38.1 million respectively, as of June 30, 2024. As of March 31, 2025, we had $8.5 million of borrowing capacity on our credit facility of which we had outstanding borrowings of $2.0 million. Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “We are encouraged by our continued growth in top line revenue as it reflects the accomplishments our sales teams have garnered in cultivating new customer relationships along with organic sales growth from our current customer base. We believe these sales efforts will lead back to profitability in the year ahead. Supply chain, customer order flow, and currency valuations continue to provide significant headwinds that we are monitoring closely. We are also encouraged by the interest level of our new TriBsyn™ product offering, and we are optimistic new products containing this innovative ingredient will be launching commercially in retail channels in the near future.” An updated investor presentation will be posted to the investor relations page on our website later today (https://www.nai-online.com/our-company/investors/). NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging, and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please see our website at http://www.nai-online.com. This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our ability to develop, maintain or increase sales to new and existing customers, our future revenue, profits and financial condition, as well as current and future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. SOURCE - Natural Alternatives International, Inc. CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or investor@nai-online.com. Web site: http://www.nai-online.com NATURAL ALTERNATIVES INTERNATIONAL, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)         (Unaudited)   (Unaudited)   Three Months Ended   Nine Months Ended   March 31,   March 31,    2025     2024     2025     2024   NET SALES$28,766  100.0% $25,136  100.0% $95,994  100.0% $84,307  100.0%Cost of goods sold 26,940  93.7%  23,214  92.4%  90,240  94.0%  78,861  93.5%Gross profit 1,826  6.3%  1,922  7.6%  5,754  6.0%  5,446  6.5%                Selling, general & administrative expenses 3,926  13.6%  3,874  15.4%  12,470  13.0%  11,455  13.6%                LOSS FROM OPERATIONS (2,100) -7.3%  (1,952) -7.8%  (6,716) -7.0%  (6,009) -7.1%                Other expense, net (542) -1.9%  (16) -0.1%  (1,205) -1.3%  (674) -0.8%LOSS BEFORE TAXES (2,642) -9.2%  (1,968) -7.8%  (7,921) -8.3%  (6,683) -7.9%                Income tax benefit (456)    (390)    (1,562)    (1,340)                  NET LOSS$(2,186)   $(1,578)   $(6,359)   $(5,343)                                  NET LOSS PER COMMON SHARE:               Basic:($0.37)   ($0.27)   ($1.07)   ($0.91)                  Diluted:($0.37)   ($0.27)   ($1.07)   ($0.91)                  WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:               Basic 5,943     5,868     5,928     5,856   Diluted 5,943     5,868     5,928     5,856                    NATURAL ALTERNATIVES INTERNATIONAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)       (unaudited)  March 31, June 30,  2025 2024      ASSETS    Cash and cash equivalents$10,611 $11,981 Accounts receivable, net 11,650  16,891 Inventories, net 26,991  24,249 Other current assets 9,267  8,489 Total current assets 58,519  61,610 Property and equipment, net 50,564  52,211 Operating lease right-of-use assets 41,682  43,537 Other noncurrent assets, net 4,179  4,984 Total Assets$154,944 $162,342      LIABILITIES AND STOCKHOLDERS’ EQUITY    Accounts payable and accrued liabilities$19,893 $19,456 Line of Credit 2,000  3,400 Mortgage note payable 9,007  9,229 Operating lease liability 47,425  47,662 Total Liabilities 78,325  79,747 Stockholders’ Equity 76,619  82,595 Total Liabilities and Stockholders’ Equity$154,944 $162,342      

Related News